- Home
- GNTA vs ABVC Comparison
GNTA vs ABVC Comparison
Compare GNTA & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | ABVC |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 30.9M |
| IPO Year | 2021 | 2009 |
Fundamental Metrics
Financial Performance| Metric | GNTA | ABVC |
|---|---|---|
| Price | $0.69 | $1.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 53.2K | ★ 123.5K |
| Earning Date | 03-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $509,589.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.71 |
| 52 Week High | $10.00 | $3.39 |
Technical Indicators
Market Signals| Indicator | GNTA | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 35.23 | 48.68 |
| Support Level | $0.58 | $0.96 |
| Resistance Level | $0.74 | $1.14 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 29.10 | 36.02 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is an industrial consolidator focused on acquiring majority or full ownership of privately held, established companies operating in Italian national-security-regulated sectors. Its acquisition activities span aerospace, defense, national security (including cybersecurity), and biotechnology/biosecurity, with a focus on businesses covered by Italy's Golden Power legislation.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.